CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
The company’s hybridization-based bait design allows researchers to detect low frequency variants consistently down to one percent variant allele frequency at a read depth of greater than 1,000×. The panels are fully customizable—researchers can select the gene, exonic, or intronic content needed to create an NGS cancer panel that meets their exact requirements.
Oxford Gene Technology, +44 (0) 1865 856826